Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 21, 2007

BioLineRx In-Licenses Anti-Inflammatory Peptide

  • BioLineRx obtained a novel peptide for the treatment of inflammatory diseases from Yissum Research Development Company of the Hebrew University of Jerusalem and Ramot at Tel Aviv University Ltd.

    "We believe that BL-4020 offers the potential for a highly effective and safe therapy utilizing a novel mechanism of action," remarks Morris C. Laster, M.D., CEO of BioLineRx.

    BL-4020 is a peptide designed to function as an anti-inflammatory agent in various diseases, such as allergic asthma and colitis. The peptide mimics ManLAM, a protein from the cell surface of Mycobacterium tuberculosis. ManLAM has been shown to modulate the function of the immune system and suppress various inflammatory diseases.

    BioLineRx expects that BL-4020, which retains the anti-inflammatory properties of ManLAM, will be effective with low toxicity. In preclinical trials, it was shown to be effective in a wide variety of animal models of inflammation, according to the company.

    The worldwide, exclusive license agreement with Yissum and Ramot includes the development and commercialization of BL-4020.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »